NorthCrest Asset Manangement LLC Sells 8,022 Shares of Halozyme Therapeutics, Inc. $HALO

NorthCrest Asset Manangement LLC cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 26.8% during the 2nd quarter, Holdings Channel.com reports. The firm owned 21,857 shares of the biopharmaceutical company’s stock after selling 8,022 shares during the quarter. NorthCrest Asset Manangement LLC’s holdings in Halozyme Therapeutics were worth $1,180,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Alliancebernstein L.P. raised its stake in Halozyme Therapeutics by 4.8% in the first quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company’s stock valued at $205,156,000 after purchasing an additional 146,677 shares in the last quarter. Congress Asset Management Co. boosted its holdings in Halozyme Therapeutics by 8.8% in the first quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company’s stock valued at $136,088,000 after acquiring an additional 172,971 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Halozyme Therapeutics by 4.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company’s stock valued at $129,478,000 after buying an additional 95,600 shares in the last quarter. TD Asset Management Inc boosted its holdings in shares of Halozyme Therapeutics by 5.8% during the 1st quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company’s stock valued at $92,642,000 after buying an additional 79,708 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. raised its position in shares of Halozyme Therapeutics by 27.3% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock worth $72,107,000 after purchasing an additional 242,167 shares during the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $74.44, for a total transaction of $1,488,800.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at $54,618,042.36. The trade was a 2.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Nicole Labrosse sold 20,000 shares of the company’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $75.71, for a total value of $1,514,200.00. Following the transaction, the chief financial officer directly owned 24,306 shares of the company’s stock, valued at approximately $1,840,207.26. This represents a 45.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 104,000 shares of company stock worth $6,771,120. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $77.81 on Friday. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The business’s 50 day moving average price is $67.13 and its 200-day moving average price is $61.08. The firm has a market capitalization of $9.10 billion, a PE ratio of 17.81, a P/E/G ratio of 0.42 and a beta of 1.19. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $77.95.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. The company had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of recent analyst reports. JMP Securities boosted their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 6th. JPMorgan Chase & Co. boosted their price objective on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Zacks Research upgraded Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 2nd. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Finally, Morgan Stanley increased their target price on Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an “overweight” rating in a research note on Monday, August 18th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $67.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.